AstraZeneca Announced Danicopan As Add-on To Ultomiris Or Soliris Improved Haemoglobin Levels And Maintained Disease Control In Patients With PNH Experiencing Signs Of Clinically Significant Extravascular Haemolysis
Portfolio Pulse from Charles Gross
AstraZeneca announced positive results from the Phase III ALPHA trial of danicopan as an add-on to Ultomiris or Soliris, showing a significant increase in haemoglobin levels and maintained disease control in patients with PNH experiencing EVH. The data was presented at the EHA Annual Meeting in Frankfurt.
June 09, 2023 | 8:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's danicopan showed positive results in Phase III ALPHA trial as an add-on to Ultomiris or Soliris, improving haemoglobin levels and maintaining disease control in PNH patients experiencing EVH.
The positive results from the Phase III ALPHA trial of danicopan as an add-on to Ultomiris or Soliris indicate a potential new treatment option for PNH patients experiencing EVH. This could lead to increased demand for AstraZeneca's products and potentially boost their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100